Pharmacotherapy of chronic kidney disease and mineral bone disorder
Authors:
- Rodrigo Azevedo de OliveiraRORodrigo Azevedo de Oliveira
- Rodrigo Bueno OliveiraRORodrigo Bueno Oliveira
- Vanda JorgettiVJVanda Jorgetti
- 15 October 2011
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 12 (17) , 2627-2640
Abstract
Introduction: Disturbances of the bone and mineral metabolism are a common complication of chronic kidney disease (CKD); these disturbances are known as CKD–mineral bone disorder (CKD-MBD). A better understanding of the pathophysiological mechanisms of CKD-MBD, along with its negative impact on other organs and systems, as well as on survival, has led to a shift in the treatment paradigm of this disorder. The use of phosphate binders changed dramatically over the last decade when noncalcium-containing phosphate binders, such as sevelamer and lanthanum carbonate, became possible alternative treatments to avoid calcium overload. Vitamin D receptor activators, such as paricalcitol and doxercalciferol, with fewer calcemic and phosphatemic effects, have also been introduced to control parathormone production and the interest in native vitamin D supplementation has grown. Furthermore, a new drug class, the calcimimetics, has recently been introduced into the therapeutic arsenal for treating secondary hyperparathyroidism. Areas covered: This review discusses the advantages and disadvantages of the above pharmacological options to treat CKD-MBD. Expert opinion: The individual-based use of phosphate binders, vitamin D and calcimimetics, separately or in combination, constitute a reasonable approach to treat CKD-MBD. These treatments aim to achieve a rigorous control of phosphorus and parathormone levels, while avoiding calcium overload.Keywords
This publication has 100 references indexed in Scilit:
- Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patientsNephrology Dialysis Transplantation, 2011
- Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney DiseaseJAMA, 2011
- Cinacalcet Improves Bone Density in Post–Kidney Transplant HyperparathyroidismTransplantation Proceedings, 2010
- Cinacalcet and achievement of the NKF/K-DOQITM recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational studyNephrology Dialysis Transplantation, 2009
- Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidismNephrology Dialysis Transplantation, 2008
- Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2008
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008
- Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of TreatmentNephron Clinical Practice, 2008
- Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patientsKidney International, 2007
- Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.Journal of Clinical Investigation, 1984